147 related articles for article (PubMed ID: 6107768)
21. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
[TBL] [Abstract][Full Text] [Related]
22. Safety of IGIV therapy and infusion-related adverse events.
Ballow M
Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
[TBL] [Abstract][Full Text] [Related]
23. Intravenous immune serum globulin in immunodeficiency.
Cunningham-Rundles C
Vox Sang; 1985; 49 Suppl 1():8-14. PubMed ID: 2416128
[TBL] [Abstract][Full Text] [Related]
24. I.v. immune globulin: efficacy and safety.
Minnefor AB; Oleske JM
Hosp Pract (Off Ed); 1987 Oct; 22(10):171-3, 177-9, 182-3 passim. PubMed ID: 2443521
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immune globulin (Gamimune).
Med Lett Drugs Ther; 1982 Sep; 24(617):81-2. PubMed ID: 7110057
[No Abstract] [Full Text] [Related]
26. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.
Melamed I; Testori A; Spirer Z
Int Rev Immunol; 2012 Dec; 31(6):451-61. PubMed ID: 23215767
[TBL] [Abstract][Full Text] [Related]
27. Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.
Roberton DM; Hosking CS; Efthimiou H; Wright S; Upton H; Colgan T; Hartman L; Schiff P
Aust N Z J Med; 1987 Oct; 17(5):495-500. PubMed ID: 3446162
[TBL] [Abstract][Full Text] [Related]
28. Three generations of immunoglobulin G preparations for clinical use.
McCue JP; Hein RH; Tenold R
Rev Infect Dis; 1986; 8 Suppl 4():S374-81. PubMed ID: 3092303
[TBL] [Abstract][Full Text] [Related]
29. Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens.
Hill HR; Bathras JM
Rev Infect Dis; 1986; 8 Suppl 4():S396-400. PubMed ID: 3092306
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.
Bresee JS; Mast EE; Coleman PJ; Baron MJ; Schonberger LB; Alter MJ; Jonas MM; Yu MY; Renzi PM; Schneider LC
JAMA; 1996 Nov; 276(19):1563-7. PubMed ID: 8918853
[TBL] [Abstract][Full Text] [Related]
31. Adverse reactions in selected patients following intravenous infusions of gamma globulin.
Day NK; Good RA; Wahn V
Am J Med; 1984 Mar; 76(3A):25-32. PubMed ID: 6231860
[TBL] [Abstract][Full Text] [Related]
32. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Shah SR
Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.
Pirofsky B; Kinzey DM
Drugs; 1992 Jan; 43(1):6-14. PubMed ID: 1372861
[TBL] [Abstract][Full Text] [Related]
34. Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25.
Schwartz RS
Am J Med; 1987 Oct; 83(4A):46-51. PubMed ID: 3118708
[TBL] [Abstract][Full Text] [Related]
35. New uses of intravenous immune globulin therapy.
Wilson NW; Bastian JF
West J Med; 1991 Apr; 154(4):461. PubMed ID: 1877192
[No Abstract] [Full Text] [Related]
36. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.
Gelfand EW; Hanna K;
J Clin Immunol; 2006 May; 26(3):284-90. PubMed ID: 16783467
[TBL] [Abstract][Full Text] [Related]
37. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy.
Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J
J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms and uses of intravenous immune globulin in primary ond secondary immune deficiency disorders. Naples, Florida, October 13-14, 1988.
J Allergy Clin Immunol; 1989 Oct; 84(4 Pt 2):565-648. PubMed ID: 2794300
[No Abstract] [Full Text] [Related]
39. FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.
Gupta S; Agrawal S; Gollapudi S; Kubagawa H
Hum Immunol; 2016 Dec; 77(12):1194-1201. PubMed ID: 27751883
[TBL] [Abstract][Full Text] [Related]
40. Recent experience with Pseudomonas aeruginosa immune globulin for the treatment of experimental pneumonia.
Pennington JE
J Hosp Infect; 1988 Aug; 12 Suppl D():55-60. PubMed ID: 2902130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
